Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

A novel antifungal drug candidate, the 1-tetrazole-based agent VT-1161 [(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol], which is currently in two phase 2b antifungal clinical trials, was found to be a tight-binding ligand...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Antimicrob Agents Chemother
Main Authors: Hoekstra, William J., Hargrove, Tatiana Y., Wawrzak, Zdzislaw, da Gama Jaen Batista, Denise, da Silva, Cristiane F., Nefertiti, Aline S. G., Rachakonda, Girish, Schotzinger, Robert J., Villalta, Fernando, Soeiro, Maria de Nazaré C., Lepesheva, Galina I.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Microbiology 2016
נושאים:
Experimental Therapeutics
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750653/
https://ncbi.nlm.nih.gov/pubmed/26643331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02287-15
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים